[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fV8qwegc1sx0yaYBFWcBe9zRYhqwNR8ilj06VCSh_Auw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":64,"rows":71},"St. Louis University",[4],151,false,17,2,12497,113,[13,16,19,21,24,27,29,31],{"name":14,"count":15},"Pregnancy",6,{"name":17,"count":18},"Interstitial Cystitis",5,{"name":20,"count":18},"Hypertension",{"name":22,"count":23},"Opioid Use",4,{"name":25,"count":26},"Endometriosis",3,{"name":28,"count":9},"Breast Cancer",{"name":30,"count":9},"Prostate Cancer",{"name":32,"count":9},"Insulin Resistance",[34,39,44,49,54,59],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05656261","APOL1 Genetic Testing in African Americans","2026-06-30","Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03823534","Post-Op Pain Control for Prophylactic Intramedullary Nailing.","2026-12-31","Ketorolac",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03295981","Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone","2027-01","Zoledronic Acid",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05249634","Testosterone Treatment in Men With Chronic Kidney Disease","2028-06","Jatenzo Pill",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT07158476","Efficacy of Methylprednisolone for Pain Control After ACL Repair","2030-09","Meloxicam 15 mg",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06055712","Antibiotic Prophylaxis in Pediatric Open Fractures","2033-09","Cefazolin",[65,66,67,68,69,70],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[72,102,120,138,156,174,199,217,271,303,325,343,361,379,397,415,438,464,482,508,526,553,580,598,625,651,675,709,731,753,775,797,831,860,885,908,938,956,974,1000,1018,1042,1066,1092,1110,1128,1155,1181,1208,1234,1252,1276,1303,1321,1347,1365,1383,1410,1428,1446,1471,1489,1515,1533,1558,1576],{"intervention":58,"totalTrials":73,"cells":74},1,{"EARLY_PHASE1":75,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":100},{"trials":76,"activeCount":77},[],0,{"trials":79,"activeCount":77},[],{"trials":81,"activeCount":77},[],{"trials":83,"activeCount":77},[],{"trials":85,"activeCount":73,"soonestReadout":57},[86],{"nctId":55,"briefTitle":56,"status":87,"phases":88,"primaryCompletion":57,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":95},"RECRUITING",[69],"2031-09","2025-10-21",90,[93,94],"ACL Surgery","Pain Management",[58,96,97,98,99],"Medrol 4 MG Oral Tablet Includes Medrol Dosepak","Gabapentin 300 mg","Hydrocodone 5Mg\u002FAcetaminophen 325Mg Tab","Ketorolac 10 Mg Oral",{"trials":101,"activeCount":77},[],{"intervention":96,"totalTrials":73,"cells":103},{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":118},{"trials":105,"activeCount":77},[],{"trials":107,"activeCount":77},[],{"trials":109,"activeCount":77},[],{"trials":111,"activeCount":77},[],{"trials":113,"activeCount":73,"soonestReadout":57},[114],{"nctId":55,"briefTitle":56,"status":87,"phases":115,"primaryCompletion":57,"completion":89,"start":90,"enrollment":91,"conditions":116,"interventions":117},[69],[93,94],[58,96,97,98,99],{"trials":119,"activeCount":77},[],{"intervention":97,"totalTrials":73,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":136},{"trials":123,"activeCount":77},[],{"trials":125,"activeCount":77},[],{"trials":127,"activeCount":77},[],{"trials":129,"activeCount":77},[],{"trials":131,"activeCount":73,"soonestReadout":57},[132],{"nctId":55,"briefTitle":56,"status":87,"phases":133,"primaryCompletion":57,"completion":89,"start":90,"enrollment":91,"conditions":134,"interventions":135},[69],[93,94],[58,96,97,98,99],{"trials":137,"activeCount":77},[],{"intervention":98,"totalTrials":73,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":154},{"trials":141,"activeCount":77},[],{"trials":143,"activeCount":77},[],{"trials":145,"activeCount":77},[],{"trials":147,"activeCount":77},[],{"trials":149,"activeCount":73,"soonestReadout":57},[150],{"nctId":55,"briefTitle":56,"status":87,"phases":151,"primaryCompletion":57,"completion":89,"start":90,"enrollment":91,"conditions":152,"interventions":153},[69],[93,94],[58,96,97,98,99],{"trials":155,"activeCount":77},[],{"intervention":99,"totalTrials":73,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":166,"NA":172},{"trials":159,"activeCount":77},[],{"trials":161,"activeCount":77},[],{"trials":163,"activeCount":77},[],{"trials":165,"activeCount":77},[],{"trials":167,"activeCount":73,"soonestReadout":57},[168],{"nctId":55,"briefTitle":56,"status":87,"phases":169,"primaryCompletion":57,"completion":89,"start":90,"enrollment":91,"conditions":170,"interventions":171},[69],[93,94],[58,96,97,98,99],{"trials":173,"activeCount":77},[],{"intervention":63,"totalTrials":73,"cells":175},{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":197},{"trials":177,"activeCount":77},[],{"trials":179,"activeCount":77},[],{"trials":181,"activeCount":77},[],{"trials":183,"activeCount":77},[],{"trials":185,"activeCount":73,"soonestReadout":62},[186],{"nctId":60,"briefTitle":61,"status":187,"phases":188,"primaryCompletion":62,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":195},"ENROLLING_BY_INVITATION",[69],"2034-01","2023-09-11",800,[193,194],"Fractures, Open","Infections",[63,196],"Cephalexin",{"trials":198,"activeCount":77},[],{"intervention":196,"totalTrials":73,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":77},[],{"trials":204,"activeCount":77},[],{"trials":206,"activeCount":77},[],{"trials":208,"activeCount":77},[],{"trials":210,"activeCount":73,"soonestReadout":62},[211],{"nctId":60,"briefTitle":61,"status":187,"phases":212,"primaryCompletion":62,"completion":189,"start":190,"enrollment":191,"conditions":213,"interventions":214},[69],[193,194],[63,196],{"trials":216,"activeCount":77},[],{"intervention":218,"totalTrials":26,"cells":219},"Acetaminophen",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":244,"NA":269},{"trials":221,"activeCount":77},[],{"trials":223,"activeCount":77},[],{"trials":225,"activeCount":77},[],{"trials":227,"activeCount":73,"soonestReadout":42},[228],{"nctId":40,"briefTitle":41,"status":87,"phases":229,"primaryCompletion":42,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":238},[68],"2027-03-31","2019-02-20",60,[234,235,236,22,237],"Bone Metastases","Lymphoma","Multiple Myeloma","Pain",[43,239,218,240,241,242,243],"Normal saline","Oxycodone Acetaminophen","Morphine","Hydrocodone\u002FAcetaminophen","Oxycodone",{"trials":245,"activeCount":77},[246,257],{"nctId":247,"briefTitle":248,"status":249,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":255},"NCT02902172","NSAID Use in Postpartum Hypertensive Women","TERMINATED",[69],"2017-10-08","2017-03-15",36,[20],[218,256],"NSAID",{"nctId":258,"briefTitle":259,"status":249,"phases":260,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":267},"NCT03677830","Postoperative Pain Control & Relief in Neonates",[69],"2024-03-07","2019-04-19",11,[265,266,22],"Pain, Postoperative","Premature Infant",[218,268],"Saline",{"trials":270,"activeCount":77},[],{"intervention":43,"totalTrials":9,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":285,"NA":301},{"trials":274,"activeCount":77},[],{"trials":276,"activeCount":77},[],{"trials":278,"activeCount":77},[],{"trials":280,"activeCount":73,"soonestReadout":42},[281],{"nctId":40,"briefTitle":41,"status":87,"phases":282,"primaryCompletion":42,"completion":230,"start":231,"enrollment":232,"conditions":283,"interventions":284},[68],[234,235,236,22,237],[43,239,218,240,241,242,243],{"trials":286,"activeCount":77},[287],{"nctId":288,"briefTitle":289,"status":290,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":300},"NCT05074056","Ketorolac on Postoperative Pain Reduction in Pediatric Patients with Adenotonsillectomy","COMPLETED",[69],"2024-12-30","2022-02-08",142,[296,297,298,299],"Adenotonsillar Hypertrophy","Obstructive Sleep Apnea","Sleep-Disordered Breathing","Acute Post Operative Pain",[43],{"trials":302,"activeCount":77},[],{"intervention":48,"totalTrials":73,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":321,"NA":323},{"trials":306,"activeCount":77},[],{"trials":308,"activeCount":77},[],{"trials":310,"activeCount":77},[],{"trials":312,"activeCount":73,"soonestReadout":47},[313],{"nctId":45,"briefTitle":46,"status":87,"phases":314,"primaryCompletion":47,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":320},[68],"2028-01","2018-05-03",120,[319],"Giant Cell Tumor of Bone",[48],{"trials":322,"activeCount":77},[],{"trials":324,"activeCount":77},[],{"intervention":239,"totalTrials":73,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":339,"NA":341},{"trials":328,"activeCount":77},[],{"trials":330,"activeCount":77},[],{"trials":332,"activeCount":77},[],{"trials":334,"activeCount":73,"soonestReadout":42},[335],{"nctId":40,"briefTitle":41,"status":87,"phases":336,"primaryCompletion":42,"completion":230,"start":231,"enrollment":232,"conditions":337,"interventions":338},[68],[234,235,236,22,237],[43,239,218,240,241,242,243],{"trials":340,"activeCount":77},[],{"trials":342,"activeCount":77},[],{"intervention":240,"totalTrials":73,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":357,"NA":359},{"trials":346,"activeCount":77},[],{"trials":348,"activeCount":77},[],{"trials":350,"activeCount":77},[],{"trials":352,"activeCount":73,"soonestReadout":42},[353],{"nctId":40,"briefTitle":41,"status":87,"phases":354,"primaryCompletion":42,"completion":230,"start":231,"enrollment":232,"conditions":355,"interventions":356},[68],[234,235,236,22,237],[43,239,218,240,241,242,243],{"trials":358,"activeCount":77},[],{"trials":360,"activeCount":77},[],{"intervention":241,"totalTrials":73,"cells":362},{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":375,"NA":377},{"trials":364,"activeCount":77},[],{"trials":366,"activeCount":77},[],{"trials":368,"activeCount":77},[],{"trials":370,"activeCount":73,"soonestReadout":42},[371],{"nctId":40,"briefTitle":41,"status":87,"phases":372,"primaryCompletion":42,"completion":230,"start":231,"enrollment":232,"conditions":373,"interventions":374},[68],[234,235,236,22,237],[43,239,218,240,241,242,243],{"trials":376,"activeCount":77},[],{"trials":378,"activeCount":77},[],{"intervention":242,"totalTrials":73,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":393,"NA":395},{"trials":382,"activeCount":77},[],{"trials":384,"activeCount":77},[],{"trials":386,"activeCount":77},[],{"trials":388,"activeCount":73,"soonestReadout":42},[389],{"nctId":40,"briefTitle":41,"status":87,"phases":390,"primaryCompletion":42,"completion":230,"start":231,"enrollment":232,"conditions":391,"interventions":392},[68],[234,235,236,22,237],[43,239,218,240,241,242,243],{"trials":394,"activeCount":77},[],{"trials":396,"activeCount":77},[],{"intervention":243,"totalTrials":73,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":411,"NA":413},{"trials":400,"activeCount":77},[],{"trials":402,"activeCount":77},[],{"trials":404,"activeCount":77},[],{"trials":406,"activeCount":73,"soonestReadout":42},[407],{"nctId":40,"briefTitle":41,"status":87,"phases":408,"primaryCompletion":42,"completion":230,"start":231,"enrollment":232,"conditions":409,"interventions":410},[68],[234,235,236,22,237],[43,239,218,240,241,242,243],{"trials":412,"activeCount":77},[],{"trials":414,"activeCount":77},[],{"intervention":53,"totalTrials":73,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":418,"activeCount":77},[],{"trials":420,"activeCount":77},[],{"trials":422,"activeCount":73,"soonestReadout":52},[423],{"nctId":50,"briefTitle":51,"status":87,"phases":424,"primaryCompletion":52,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":431},[67],"2028-12","2022-03-15",20,[429,430],"Hypogonadism, Male","Kidney Disease, Chronic",[53],{"trials":433,"activeCount":77},[],{"trials":435,"activeCount":77},[],{"trials":437,"activeCount":77},[],{"intervention":38,"totalTrials":73,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":450},{"trials":441,"activeCount":77},[],{"trials":443,"activeCount":77},[],{"trials":445,"activeCount":77},[],{"trials":447,"activeCount":77},[],{"trials":449,"activeCount":77},[],{"trials":451,"activeCount":73,"soonestReadout":37},[452],{"nctId":35,"briefTitle":36,"status":87,"phases":453,"primaryCompletion":37,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":463},[],"2027-06-30","2019-01-24",600,[458,459,460,461,462],"Genetic Predisposition","Chronic Kidney Diseases","Nephropathy","APOL1 Associated Kidney Disease","Disparities",[38],{"intervention":256,"totalTrials":73,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":480},{"trials":467,"activeCount":77},[],{"trials":469,"activeCount":77},[],{"trials":471,"activeCount":77},[],{"trials":473,"activeCount":77},[],{"trials":475,"activeCount":77},[476],{"nctId":247,"briefTitle":248,"status":249,"phases":477,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":478,"interventions":479},[69],[20],[218,256],{"trials":481,"activeCount":77},[],{"intervention":483,"totalTrials":73,"cells":484},"Trimethoprim-sulfamethoxazole",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":506},{"trials":486,"activeCount":77},[],{"trials":488,"activeCount":77},[],{"trials":490,"activeCount":77},[],{"trials":492,"activeCount":77},[],{"trials":494,"activeCount":77},[495],{"nctId":496,"briefTitle":497,"status":290,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":505},"NCT00679302","Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management",[69],"2008-02","2008-05","2006-07",161,[504],"Skin Diseases, Infectious",[483],{"trials":507,"activeCount":77},[],{"intervention":268,"totalTrials":73,"cells":509},{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":524},{"trials":511,"activeCount":77},[],{"trials":513,"activeCount":77},[],{"trials":515,"activeCount":77},[],{"trials":517,"activeCount":77},[],{"trials":519,"activeCount":77},[520],{"nctId":258,"briefTitle":259,"status":249,"phases":521,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":522,"interventions":523},[69],[265,266,22],[218,268],{"trials":525,"activeCount":77},[],{"intervention":527,"totalTrials":73,"cells":528},"Povidone-Iodine",{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":551},{"trials":530,"activeCount":77},[],{"trials":532,"activeCount":77},[],{"trials":534,"activeCount":77},[],{"trials":536,"activeCount":77},[],{"trials":538,"activeCount":77},[539],{"nctId":540,"briefTitle":541,"status":290,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":232,"conditions":545,"interventions":550},"NCT05919888","SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty",[69],"2023-11-14","2023-06-26",[546,547,548,549],"Surgery","Surgical Site Infection","Cutibacterium Acnes","Prosthetic-joint Infection",[527],{"trials":552,"activeCount":77},[],{"intervention":554,"totalTrials":73,"cells":555},"Inactivated Influenza Vaccine",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":564,"NA":578},{"trials":557,"activeCount":77},[],{"trials":559,"activeCount":77},[],{"trials":561,"activeCount":77},[],{"trials":563,"activeCount":77},[],{"trials":565,"activeCount":77},[566],{"nctId":567,"briefTitle":568,"status":290,"phases":569,"primaryCompletion":570,"completion":571,"start":572,"enrollment":573,"conditions":574,"interventions":576},"NCT03101462","Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years",[69],"2011-05-13","2011-11-09","2011-02-24",38,[575],"Influenza",[554,577],"Live Attenuated Influenza Vaccine",{"trials":579,"activeCount":77},[],{"intervention":577,"totalTrials":73,"cells":581},{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":590,"NA":596},{"trials":583,"activeCount":77},[],{"trials":585,"activeCount":77},[],{"trials":587,"activeCount":77},[],{"trials":589,"activeCount":77},[],{"trials":591,"activeCount":77},[592],{"nctId":567,"briefTitle":568,"status":290,"phases":593,"primaryCompletion":570,"completion":571,"start":572,"enrollment":573,"conditions":594,"interventions":595},[69],[575],[554,577],{"trials":597,"activeCount":77},[],{"intervention":599,"totalTrials":73,"cells":600},"Transdermal Methylphenidate",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":623},{"trials":602,"activeCount":77},[],{"trials":604,"activeCount":77},[],{"trials":606,"activeCount":77},[],{"trials":608,"activeCount":77},[],{"trials":610,"activeCount":77},[611],{"nctId":612,"briefTitle":613,"status":249,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":622},"NCT01825577","Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.",[69],"2015-02","2012-11",14,[619,620,621],"Dementia","Accidental Falls","Apathy",[599],{"trials":624,"activeCount":77},[],{"intervention":626,"totalTrials":73,"cells":627},"Orlistat",{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":634,"PHASE4":636,"NA":649},{"trials":629,"activeCount":77},[],{"trials":631,"activeCount":77},[],{"trials":633,"activeCount":77},[],{"trials":635,"activeCount":77},[],{"trials":637,"activeCount":77},[638],{"nctId":639,"briefTitle":640,"status":290,"phases":641,"completion":642,"start":643,"enrollment":644,"conditions":645,"interventions":648},"NCT00160407","Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)",[69],"2006-12","2003-10",50,[646,647],"Fatty Liver","Hepatitis",[626],{"trials":650,"activeCount":77},[],{"intervention":652,"totalTrials":73,"cells":653},"Polyethylene Glycol 3350",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":660,"PHASE4":662,"NA":673},{"trials":655,"activeCount":77},[],{"trials":657,"activeCount":77},[],{"trials":659,"activeCount":77},[],{"trials":661,"activeCount":77},[],{"trials":663,"activeCount":77},[664],{"nctId":665,"briefTitle":666,"status":290,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":26,"conditions":670,"interventions":672},"NCT04210427","Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit",[69],"2023-06-06","2019-12-12",[671],"Cystic Fibrosis Gastrointestinal Disease",[652],{"trials":674,"activeCount":77},[],{"intervention":676,"totalTrials":9,"cells":677},"filgrastim",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":703,"PHASE4":705,"NA":707},{"trials":679,"activeCount":77},[],{"trials":681,"activeCount":77},[],{"trials":683,"activeCount":77},[684,696],{"nctId":685,"briefTitle":686,"status":687,"phases":688,"start":689,"enrollment":644,"conditions":690,"interventions":691},"NCT00002628","Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer","UNKNOWN",[66,67],"1994-11",[28],[676,692,693,694,695],"carboplatin","cyclophosphamide","mesna","paclitaxel",{"nctId":697,"briefTitle":698,"status":687,"phases":699,"start":689,"enrollment":700,"conditions":701,"interventions":702},"NCT00002627","Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer",[66,67],30,[28],[676,692,693,694,695],{"trials":704,"activeCount":77},[],{"trials":706,"activeCount":77},[],{"trials":708,"activeCount":77},[],{"intervention":692,"totalTrials":9,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":712,"activeCount":77},[],{"trials":714,"activeCount":77},[],{"trials":716,"activeCount":77},[717,721],{"nctId":685,"briefTitle":686,"status":687,"phases":718,"start":689,"enrollment":644,"conditions":719,"interventions":720},[66,67],[28],[676,692,693,694,695],{"nctId":697,"briefTitle":698,"status":687,"phases":722,"start":689,"enrollment":700,"conditions":723,"interventions":724},[66,67],[28],[676,692,693,694,695],{"trials":726,"activeCount":77},[],{"trials":728,"activeCount":77},[],{"trials":730,"activeCount":77},[],{"intervention":693,"totalTrials":9,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":747,"PHASE4":749,"NA":751},{"trials":734,"activeCount":77},[],{"trials":736,"activeCount":77},[],{"trials":738,"activeCount":77},[739,743],{"nctId":685,"briefTitle":686,"status":687,"phases":740,"start":689,"enrollment":644,"conditions":741,"interventions":742},[66,67],[28],[676,692,693,694,695],{"nctId":697,"briefTitle":698,"status":687,"phases":744,"start":689,"enrollment":700,"conditions":745,"interventions":746},[66,67],[28],[676,692,693,694,695],{"trials":748,"activeCount":77},[],{"trials":750,"activeCount":77},[],{"trials":752,"activeCount":77},[],{"intervention":694,"totalTrials":9,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":756,"activeCount":77},[],{"trials":758,"activeCount":77},[],{"trials":760,"activeCount":77},[761,765],{"nctId":685,"briefTitle":686,"status":687,"phases":762,"start":689,"enrollment":644,"conditions":763,"interventions":764},[66,67],[28],[676,692,693,694,695],{"nctId":697,"briefTitle":698,"status":687,"phases":766,"start":689,"enrollment":700,"conditions":767,"interventions":768},[66,67],[28],[676,692,693,694,695],{"trials":770,"activeCount":77},[],{"trials":772,"activeCount":77},[],{"trials":774,"activeCount":77},[],{"intervention":695,"totalTrials":9,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":778,"activeCount":77},[],{"trials":780,"activeCount":77},[],{"trials":782,"activeCount":77},[783,787],{"nctId":685,"briefTitle":686,"status":687,"phases":784,"start":689,"enrollment":644,"conditions":785,"interventions":786},[66,67],[28],[676,692,693,694,695],{"nctId":697,"briefTitle":698,"status":687,"phases":788,"start":689,"enrollment":700,"conditions":789,"interventions":790},[66,67],[28],[676,692,693,694,695],{"trials":792,"activeCount":77},[],{"trials":794,"activeCount":77},[],{"trials":796,"activeCount":77},[],{"intervention":798,"totalTrials":9,"cells":799},"Pioglitazone 30 mg",{"EARLY_PHASE1":800,"PHASE1":813,"PHASE2":815,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":801,"activeCount":77},[802],{"nctId":803,"briefTitle":804,"status":805,"phases":806,"primaryCompletion":807,"completion":807,"start":808,"enrollment":77,"conditions":809,"interventions":810},"NCT04658849","Insulin Resistance Following ADT for Prostate CA","WITHDRAWN",[65],"2023-03-29","2020-12-02",[32,30],[811,812],"Pioglitazone 30 Mg Oral","Pioglitazone placebo",{"trials":814,"activeCount":77},[],{"trials":816,"activeCount":77},[817],{"nctId":818,"briefTitle":819,"status":805,"phases":820,"primaryCompletion":821,"completion":821,"start":822,"enrollment":77,"conditions":823,"interventions":824},"NCT04995978","Insulin Resistance and Androgen Deprivation Therapy",[67],"2023-01-18","2021-12-01",[30,32],[798],{"trials":826,"activeCount":77},[],{"trials":828,"activeCount":77},[],{"trials":830,"activeCount":77},[],{"intervention":832,"totalTrials":73,"cells":833},"Pembrolizumab",{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":835,"activeCount":77},[],{"trials":837,"activeCount":77},[],{"trials":839,"activeCount":77},[840],{"nctId":841,"briefTitle":842,"status":290,"phases":843,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":853},"NCT02306850","Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma",[67],"2018-06-08","2015-01",10,[848,849,850,851,852],"Unresectable Malignant Neoplasm","Melanoma","Metastatic Melanoma","Stage IV Melanoma","Stage III Melanoma",[832],{"trials":855,"activeCount":77},[],{"trials":857,"activeCount":77},[],{"trials":859,"activeCount":77},[],{"intervention":861,"totalTrials":73,"cells":862},"Fosaprepitant",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":879,"PHASE4":881,"NA":883},{"trials":864,"activeCount":77},[],{"trials":866,"activeCount":77},[],{"trials":868,"activeCount":77},[869],{"nctId":870,"briefTitle":871,"status":249,"phases":872,"primaryCompletion":873,"completion":873,"start":874,"enrollment":875,"conditions":876,"interventions":878},"NCT01874119","Fosaprepitant for N\u002FV With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma",[67],"2015-12-03","2013-09",13,[877],"Chemotherapy-induced Nausea and Vomiting",[861],{"trials":880,"activeCount":77},[],{"trials":882,"activeCount":77},[],{"trials":884,"activeCount":77},[],{"intervention":886,"totalTrials":73,"cells":887},"Progesterone 200 MG",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":889,"activeCount":77},[],{"trials":891,"activeCount":77},[],{"trials":893,"activeCount":77},[894],{"nctId":895,"briefTitle":896,"status":249,"phases":897,"primaryCompletion":821,"completion":821,"start":898,"enrollment":18,"conditions":899,"interventions":901},"NCT04534881","Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen",[67],"2020-10-20",[900],"Transgender Persons",[886],{"trials":903,"activeCount":77},[],{"trials":905,"activeCount":77},[],{"trials":907,"activeCount":77},[],{"intervention":909,"totalTrials":73,"cells":910},"Abciximab",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":912,"activeCount":77},[],{"trials":914,"activeCount":77},[],{"trials":916,"activeCount":77},[917],{"nctId":918,"briefTitle":919,"status":805,"phases":920,"primaryCompletion":921,"completion":921,"start":922,"enrollment":77,"conditions":923,"interventions":929},"NCT01932554","Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis",[67],"2015-03","2013-11",[924,925,926,927,928],"Sickle Cell Disease","Hb-SS Disease With Vasoocclusive Pain","Hemoglobin SS Disease With Vasoocclusive Crisis","Other Sickle Cell Disease With Vaso-Occlusive Pain","Hemoglobin SS Disease With Crisis",[909,930,931],"Ibuprofen","Parenteral narcotic",{"trials":933,"activeCount":77},[],{"trials":935,"activeCount":77},[],{"trials":937,"activeCount":77},[],{"intervention":930,"totalTrials":73,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":941,"activeCount":77},[],{"trials":943,"activeCount":77},[],{"trials":945,"activeCount":77},[946],{"nctId":918,"briefTitle":919,"status":805,"phases":947,"primaryCompletion":921,"completion":921,"start":922,"enrollment":77,"conditions":948,"interventions":949},[67],[924,925,926,927,928],[909,930,931],{"trials":951,"activeCount":77},[],{"trials":953,"activeCount":77},[],{"trials":955,"activeCount":77},[],{"intervention":931,"totalTrials":73,"cells":957},{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":959,"activeCount":77},[],{"trials":961,"activeCount":77},[],{"trials":963,"activeCount":77},[964],{"nctId":918,"briefTitle":919,"status":805,"phases":965,"primaryCompletion":921,"completion":921,"start":922,"enrollment":77,"conditions":966,"interventions":967},[67],[924,925,926,927,928],[909,930,931],{"trials":969,"activeCount":77},[],{"trials":971,"activeCount":77},[],{"trials":973,"activeCount":77},[],{"intervention":975,"totalTrials":73,"cells":976},"adenosine",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":992,"PHASE3":994,"PHASE4":996,"NA":998},{"trials":978,"activeCount":77},[],{"trials":980,"activeCount":77},[981],{"nctId":982,"briefTitle":983,"status":290,"phases":984,"primaryCompletion":985,"completion":985,"start":986,"enrollment":987,"conditions":988,"interventions":990},"NCT01161121","Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia",[66],"2013-04","2010-07",46,[989],"Coronary Artery Disease",[975,991],"regadenoson",{"trials":993,"activeCount":77},[],{"trials":995,"activeCount":77},[],{"trials":997,"activeCount":77},[],{"trials":999,"activeCount":77},[],{"intervention":991,"totalTrials":73,"cells":1001},{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1010,"PHASE3":1012,"PHASE4":1014,"NA":1016},{"trials":1003,"activeCount":77},[],{"trials":1005,"activeCount":77},[1006],{"nctId":982,"briefTitle":983,"status":290,"phases":1007,"primaryCompletion":985,"completion":985,"start":986,"enrollment":987,"conditions":1008,"interventions":1009},[66],[989],[975,991],{"trials":1011,"activeCount":77},[],{"trials":1013,"activeCount":77},[],{"trials":1015,"activeCount":77},[],{"trials":1017,"activeCount":77},[],{"intervention":1019,"totalTrials":73,"cells":1020},"Subcutaneous immunoglobulins",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1034,"PHASE3":1036,"PHASE4":1038,"NA":1040},{"trials":1022,"activeCount":77},[],{"trials":1024,"activeCount":77},[1025],{"nctId":1026,"briefTitle":1027,"status":249,"phases":1028,"primaryCompletion":1029,"completion":1029,"start":1030,"enrollment":23,"conditions":1031,"interventions":1033},"NCT01828294","Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis",[66],"2017-12","2011-10",[1032],"Myasthenia Gravis",[1019],{"trials":1035,"activeCount":77},[],{"trials":1037,"activeCount":77},[],{"trials":1039,"activeCount":77},[],{"trials":1041,"activeCount":77},[],{"intervention":1043,"totalTrials":73,"cells":1044},"Melatonin",{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1058,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1046,"activeCount":77},[],{"trials":1048,"activeCount":77},[1049],{"nctId":1050,"briefTitle":1051,"status":805,"phases":1052,"primaryCompletion":1029,"completion":1053,"start":1054,"enrollment":77,"conditions":1055,"interventions":1057},"NCT01904786","Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy",[66],"2018-11","2014-04",[1056],"Newborn Hypoxic Ischemic Encephalopathy",[1043],{"trials":1059,"activeCount":77},[],{"trials":1061,"activeCount":77},[],{"trials":1063,"activeCount":77},[],{"trials":1065,"activeCount":77},[],{"intervention":1067,"totalTrials":73,"cells":1068},"Tricyclic Antidepressants",{"EARLY_PHASE1":1069,"PHASE1":1082,"PHASE2":1084,"PHASE3":1086,"PHASE4":1088,"NA":1090},{"trials":1070,"activeCount":77},[1071],{"nctId":1072,"briefTitle":1073,"status":290,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":9,"conditions":1077,"interventions":1080},"NCT02851914","SSRIs vs. TCAs for Depression in ALS Patients",[65],"2019-05-30","2015-07-21",[1078,1079],"Depression","Amyotrophic Lateral Sclerosis",[1067,1081],"Selective Serotonin Uptake Inhibitors",{"trials":1083,"activeCount":77},[],{"trials":1085,"activeCount":77},[],{"trials":1087,"activeCount":77},[],{"trials":1089,"activeCount":77},[],{"trials":1091,"activeCount":77},[],{"intervention":1081,"totalTrials":73,"cells":1093},{"EARLY_PHASE1":1094,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1095,"activeCount":77},[1096],{"nctId":1072,"briefTitle":1073,"status":290,"phases":1097,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":9,"conditions":1098,"interventions":1099},[65],[1078,1079],[1067,1081],{"trials":1101,"activeCount":77},[],{"trials":1103,"activeCount":77},[],{"trials":1105,"activeCount":77},[],{"trials":1107,"activeCount":77},[],{"trials":1109,"activeCount":77},[],{"intervention":812,"totalTrials":73,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1113,"activeCount":77},[1114],{"nctId":803,"briefTitle":804,"status":805,"phases":1115,"primaryCompletion":807,"completion":807,"start":808,"enrollment":77,"conditions":1116,"interventions":1117},[65],[32,30],[811,812],{"trials":1119,"activeCount":77},[],{"trials":1121,"activeCount":77},[],{"trials":1123,"activeCount":77},[],{"trials":1125,"activeCount":77},[],{"trials":1127,"activeCount":77},[],{"intervention":1129,"totalTrials":73,"cells":1130},"Amoxicillin",{"EARLY_PHASE1":1131,"PHASE1":1145,"PHASE2":1147,"PHASE3":1149,"PHASE4":1151,"NA":1153},{"trials":1132,"activeCount":77},[1133],{"nctId":1134,"briefTitle":1135,"status":290,"phases":1136,"primaryCompletion":1137,"completion":1138,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1144},"NCT03582605","Antibiotics Prior to Mini-screw Implant Insertion",[65],"2020-10-01","2020-11-01","2018-08-07",31,[1142,1143],"Inflammation at Mini-screw Insertion Site","Mobility, Mini-screw",[1129],{"trials":1146,"activeCount":77},[],{"trials":1148,"activeCount":77},[],{"trials":1150,"activeCount":77},[],{"trials":1152,"activeCount":77},[],{"trials":1154,"activeCount":77},[],{"intervention":1156,"totalTrials":73,"cells":1157},"Metformin",{"EARLY_PHASE1":1158,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1159,"activeCount":77},[1160],{"nctId":1161,"briefTitle":1162,"status":290,"phases":1163,"primaryCompletion":1164,"completion":1164,"start":1165,"enrollment":1166,"conditions":1167,"interventions":1170},"NCT03445702","Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I",[65],"2020-10-27","2018-10-15",15,[1168,1169],"Diabetes Mellitus, Type 2","Metformin Adverse Reaction",[1156],{"trials":1172,"activeCount":77},[],{"trials":1174,"activeCount":77},[],{"trials":1176,"activeCount":77},[],{"trials":1178,"activeCount":77},[],{"trials":1180,"activeCount":77},[],{"intervention":1182,"totalTrials":73,"cells":1183},"Gadoteric Acid",{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1185,"activeCount":77},[],{"trials":1187,"activeCount":77},[],{"trials":1189,"activeCount":77},[],{"trials":1191,"activeCount":77},[],{"trials":1193,"activeCount":77},[],{"trials":1195,"activeCount":77},[1196],{"nctId":1197,"briefTitle":1198,"status":290,"phases":1199,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1207},"NCT02609919","Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age",[],"2019-07-18","2019-07-19","2016-01",150,[1205,1206],"Adverse Reaction to Drug","Allergic Reaction to Contrast Media",[1182],{"intervention":1209,"totalTrials":73,"cells":1210},"ketoconazole 2% foam",{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1212,"activeCount":77},[],{"trials":1214,"activeCount":77},[],{"trials":1216,"activeCount":77},[],{"trials":1218,"activeCount":77},[],{"trials":1220,"activeCount":77},[],{"trials":1222,"activeCount":77},[1223],{"nctId":1224,"briefTitle":1225,"status":290,"phases":1226,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":1229,"conditions":1230,"interventions":1232},"NCT01203189","Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo",[70],"2013-06","2010-09",23,[1231],"Seborrheic Dermatitis",[1209,1233],"ketoconazole 2% shampoo",{"intervention":1233,"totalTrials":73,"cells":1235},{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1237,"activeCount":77},[],{"trials":1239,"activeCount":77},[],{"trials":1241,"activeCount":77},[],{"trials":1243,"activeCount":77},[],{"trials":1245,"activeCount":77},[],{"trials":1247,"activeCount":77},[1248],{"nctId":1224,"briefTitle":1225,"status":290,"phases":1249,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":1229,"conditions":1250,"interventions":1251},[70],[1231],[1209,1233],{"intervention":1253,"totalTrials":73,"cells":1254},"Misoprostol",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1261,"PHASE4":1263,"NA":1265},{"trials":1256,"activeCount":77},[],{"trials":1258,"activeCount":77},[],{"trials":1260,"activeCount":77},[],{"trials":1262,"activeCount":77},[],{"trials":1264,"activeCount":77},[],{"trials":1266,"activeCount":77},[1267],{"nctId":1268,"briefTitle":1269,"status":249,"phases":1270,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":263,"conditions":1273,"interventions":1275},"NCT02534883","Cervical Ripening in Postmenopausal Women",[70],"2016-12","2015-08",[1274],"Stenosis of Cervix",[1253],{"intervention":1277,"totalTrials":73,"cells":1278},"SmartMouth Clinical DDS mouthrinse",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1289},{"trials":1280,"activeCount":77},[],{"trials":1282,"activeCount":77},[],{"trials":1284,"activeCount":77},[],{"trials":1286,"activeCount":77},[],{"trials":1288,"activeCount":77},[],{"trials":1290,"activeCount":77},[1291],{"nctId":1292,"briefTitle":1293,"status":290,"phases":1294,"primaryCompletion":1295,"completion":1295,"start":1296,"enrollment":1297,"conditions":1298,"interventions":1301},"NCT02709785","SmartMouth Advanced Clinical Formula Clinical Research Design Protocol",[70],"2017-05","2016-03",80,[1299,1300],"Gingivitis","Periodontitis",[1277,1302],"0.12% chlorhexidine rinse",{"intervention":1302,"totalTrials":73,"cells":1304},{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1306,"activeCount":77},[],{"trials":1308,"activeCount":77},[],{"trials":1310,"activeCount":77},[],{"trials":1312,"activeCount":77},[],{"trials":1314,"activeCount":77},[],{"trials":1316,"activeCount":77},[1317],{"nctId":1292,"briefTitle":1293,"status":290,"phases":1318,"primaryCompletion":1295,"completion":1295,"start":1296,"enrollment":1297,"conditions":1319,"interventions":1320},[70],[1299,1300],[1277,1302],{"intervention":1322,"totalTrials":73,"cells":1323},"Rifapentine 600 mg orally",{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1330,"PHASE4":1332,"NA":1334},{"trials":1325,"activeCount":77},[],{"trials":1327,"activeCount":77},[],{"trials":1329,"activeCount":77},[],{"trials":1331,"activeCount":77},[],{"trials":1333,"activeCount":77},[],{"trials":1335,"activeCount":77},[1336],{"nctId":1337,"briefTitle":1338,"status":805,"phases":1339,"primaryCompletion":1340,"completion":1340,"start":1341,"enrollment":77,"conditions":1342,"interventions":1344},"NCT03783728","Video Based Directly Observed Therapy for Latent TB",[],"2020-01-31","2019-06-30",[1343],"Latent Tuberculosis",[1322,1345,1346],"Isoniazid 900 mg orally","Pyridoxine 50 mg orally",{"intervention":1345,"totalTrials":73,"cells":1348},{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1355,"PHASE4":1357,"NA":1359},{"trials":1350,"activeCount":77},[],{"trials":1352,"activeCount":77},[],{"trials":1354,"activeCount":77},[],{"trials":1356,"activeCount":77},[],{"trials":1358,"activeCount":77},[],{"trials":1360,"activeCount":77},[1361],{"nctId":1337,"briefTitle":1338,"status":805,"phases":1362,"primaryCompletion":1340,"completion":1340,"start":1341,"enrollment":77,"conditions":1363,"interventions":1364},[],[1343],[1322,1345,1346],{"intervention":1346,"totalTrials":73,"cells":1366},{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1368,"activeCount":77},[],{"trials":1370,"activeCount":77},[],{"trials":1372,"activeCount":77},[],{"trials":1374,"activeCount":77},[],{"trials":1376,"activeCount":77},[],{"trials":1378,"activeCount":77},[1379],{"nctId":1337,"briefTitle":1338,"status":805,"phases":1380,"primaryCompletion":1340,"completion":1340,"start":1341,"enrollment":77,"conditions":1381,"interventions":1382},[],[1343],[1322,1345,1346],{"intervention":1384,"totalTrials":73,"cells":1385},"Metoclopramide",{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1387,"activeCount":77},[],{"trials":1389,"activeCount":77},[],{"trials":1391,"activeCount":77},[],{"trials":1393,"activeCount":77},[],{"trials":1395,"activeCount":77},[],{"trials":1397,"activeCount":77},[1398],{"nctId":1399,"briefTitle":1400,"status":290,"phases":1401,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":1404,"conditions":1405,"interventions":1407},"NCT02295280","A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.",[70],"2014-11","2012-01",70,[1406],"Headache",[1384,1408,1409],"Diphenhydramine","Codeine",{"intervention":1408,"totalTrials":73,"cells":1411},{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1420,"NA":1422},{"trials":1413,"activeCount":77},[],{"trials":1415,"activeCount":77},[],{"trials":1417,"activeCount":77},[],{"trials":1419,"activeCount":77},[],{"trials":1421,"activeCount":77},[],{"trials":1423,"activeCount":77},[1424],{"nctId":1399,"briefTitle":1400,"status":290,"phases":1425,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":1404,"conditions":1426,"interventions":1427},[70],[1406],[1384,1408,1409],{"intervention":1409,"totalTrials":73,"cells":1429},{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1431,"activeCount":77},[],{"trials":1433,"activeCount":77},[],{"trials":1435,"activeCount":77},[],{"trials":1437,"activeCount":77},[],{"trials":1439,"activeCount":77},[],{"trials":1441,"activeCount":77},[1442],{"nctId":1399,"briefTitle":1400,"status":290,"phases":1443,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":1404,"conditions":1444,"interventions":1445},[70],[1406],[1384,1408,1409],{"intervention":1447,"totalTrials":73,"cells":1448},"testosterone cypionate",{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1450,"activeCount":77},[],{"trials":1452,"activeCount":77},[],{"trials":1454,"activeCount":77},[],{"trials":1456,"activeCount":77},[],{"trials":1458,"activeCount":77},[],{"trials":1460,"activeCount":77},[1461],{"nctId":1462,"briefTitle":1463,"status":249,"phases":1464,"primaryCompletion":821,"completion":821,"start":1465,"enrollment":23,"conditions":1466,"interventions":1469},"NCT04551144","Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors",[],"2020-10-06",[1467,1468],"Gender Incongruence","Transgenderism",[1447,1470],"Estradiol Valerate",{"intervention":1470,"totalTrials":73,"cells":1472},{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1474,"activeCount":77},[],{"trials":1476,"activeCount":77},[],{"trials":1478,"activeCount":77},[],{"trials":1480,"activeCount":77},[],{"trials":1482,"activeCount":77},[],{"trials":1484,"activeCount":77},[1485],{"nctId":1462,"briefTitle":1463,"status":249,"phases":1486,"primaryCompletion":821,"completion":821,"start":1465,"enrollment":23,"conditions":1487,"interventions":1488},[],[1467,1468],[1447,1470],{"intervention":1490,"totalTrials":73,"cells":1491},"nortriptyline",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1493,"activeCount":77},[],{"trials":1495,"activeCount":77},[],{"trials":1497,"activeCount":77},[],{"trials":1499,"activeCount":77},[],{"trials":1501,"activeCount":77},[],{"trials":1503,"activeCount":77},[1504],{"nctId":1505,"briefTitle":1506,"status":249,"phases":1507,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":1511,"interventions":1513},"NCT02169830","Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine",[70],"2019-10-30","2014-08-22",35,[1512],"Migraine Disorders",[1490,1514],"Topiramate",{"intervention":1514,"totalTrials":73,"cells":1516},{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1523,"PHASE4":1525,"NA":1527},{"trials":1518,"activeCount":77},[],{"trials":1520,"activeCount":77},[],{"trials":1522,"activeCount":77},[],{"trials":1524,"activeCount":77},[],{"trials":1526,"activeCount":77},[],{"trials":1528,"activeCount":77},[1529],{"nctId":1505,"briefTitle":1506,"status":249,"phases":1530,"primaryCompletion":1508,"completion":1508,"start":1509,"enrollment":1510,"conditions":1531,"interventions":1532},[70],[1512],[1490,1514],{"intervention":1534,"totalTrials":73,"cells":1535},"Labetalol",{"EARLY_PHASE1":1536,"PHASE1":1538,"PHASE2":1540,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1537,"activeCount":77},[],{"trials":1539,"activeCount":77},[],{"trials":1541,"activeCount":77},[],{"trials":1543,"activeCount":77},[],{"trials":1545,"activeCount":77},[],{"trials":1547,"activeCount":77},[1548],{"nctId":1549,"briefTitle":1550,"status":805,"phases":1551,"primaryCompletion":1552,"completion":1552,"start":1553,"enrollment":77,"conditions":1554,"interventions":1555},"NCT02933593","Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols",[70],"2017-01","2016-08",[20],[1534,1556,1557],"Hydralazine","nifedipine",{"intervention":1556,"totalTrials":73,"cells":1559},{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1566,"PHASE4":1568,"NA":1570},{"trials":1561,"activeCount":77},[],{"trials":1563,"activeCount":77},[],{"trials":1565,"activeCount":77},[],{"trials":1567,"activeCount":77},[],{"trials":1569,"activeCount":77},[],{"trials":1571,"activeCount":77},[1572],{"nctId":1549,"briefTitle":1550,"status":805,"phases":1573,"primaryCompletion":1552,"completion":1552,"start":1553,"enrollment":77,"conditions":1574,"interventions":1575},[70],[20],[1534,1556,1557],{"intervention":1557,"totalTrials":73,"cells":1577},{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1584,"PHASE4":1586,"NA":1588},{"trials":1579,"activeCount":77},[],{"trials":1581,"activeCount":77},[],{"trials":1583,"activeCount":77},[],{"trials":1585,"activeCount":77},[],{"trials":1587,"activeCount":77},[],{"trials":1589,"activeCount":77},[1590],{"nctId":1549,"briefTitle":1550,"status":805,"phases":1591,"primaryCompletion":1552,"completion":1552,"start":1553,"enrollment":77,"conditions":1592,"interventions":1593},[70],[20],[1534,1556,1557]]